Pharmaceutical Mail. Mabxience, the Chemo group company focused on the development of biosimilar monoclonal antibodies, intends to have its new León plant at full capacity between 2020 and 2023. This was announced this week at its official inauguration by Carlos Bañado, the company's CEO, and Luisa Amoedo, director of the plant. "The growth figures for the volume of work will be set by the market, but the estimates are very good," indicated Bañado, who insisted that, in his opinion, the landing of these biologicals will bring aggressive discounts in price and more than 30 percent compared to brand originals.

READ MORE